Such mutations are found in a wide variety of human tumors and are particularly common in lower-grade gliomas, with 70%–80% of patients with grade II and III astrocytomas and oligodendrogliomas harboring IDH1 mutations (Yan et al. 2009). This evidence concerns the gene IDH1 and central nervous system cancer.